Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR

Drug design of protein kinase inhibitors is now greatly enabled by thousands of publicly available X-ray structures, extensive ligand binding data, and optimized scaffolds coming off patent. The extensive data begin to enable design against a spectrum of targets (polypharmacology); however, the data...

Descripción completa

Detalles Bibliográficos
Autores principales: Narayanan, Dilip, Gani, Osman A. B. S. M., Gruber, Franz X. E., Engh, Richard A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496928/
https://www.ncbi.nlm.nih.gov/pubmed/29086093
http://dx.doi.org/10.1186/s13321-017-0229-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496928/
https://www.ncbi.nlm.nih.gov/pubmed/29086093
http://dx.doi.org/10.1186/s13321-017-0229-8

Ejemplares similares